Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 286 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.” December 6, 2019 Researchers May Be Able to Predict Breast Cancer Metastasis by Changes... December 3, 2021 Five Questions With…Francisco. March 17, 2022 Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ February 1, 2022 Load more HOT NEWS College Student Rescues Cats Between Classes, Working 2 Jobs, And Planning... Trial Highlights Complexities of Targeted Therapy for Pancreatic Cancer Treatment with Nivolumab and Low-Dose Ipilimumab is Effective and Tolerable in... Contraception and cancer – a look behind the headlines
